Category Specific RSS

pxs

Pharmaxis streamlines operations with $2m sale of Australian distribution rights

Having successfully developed a number of drugs through to regulatory approval and commercial sales, Pharmaxis (ASX: PXS) is set to…

4 years ago

First cohort responds well to Pharmaxis cancer treatment drug – next phase of clinical trial fully subscribed

Promising early study results released today by clinical stage drug development company Pharmaxis (ASX: PXS), should be a reason for…

4 years ago

Spray-on skin revenue exceeds initial forecasts

The inventors of “spray-on skin”, Avita Medical (ASX: AVH) have today released their financial results for the fiscal fourth quarter…

4 years ago

Karst backs Aussie small cap following hugely successful pharma strategy

Leading fund manager Karst Peak Capital has secured a significant interest in a little-known Aussie pharmaceuticals research company, following the…

4 years ago

Pharmaxis streamlines operations with $2m sale of Russian distribution rights

Streamlining operations to focus on the most profitable side of their pharmaceuticals manufacturing business, Pharmaxis (ASX: PXS) has shored up…

5 years ago

Pharmaxis shares present untapped value as the drug developer pursues a rare cancer therapy

In biotech circles, tackling a rare and difficult disease with few patients does not necessarily equate to targeting an unprofitable…

5 years ago